Zobrazeno 1 - 10
of 206
pro vyhledávání: '"Kenneth H Shain"'
Autor:
Ajai Chari, Jonathan L. Kaufman, Jacob Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Rebecca Silbermann, Luciano J. Costa, Larry D. Anderson, Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Peter M. Voorhees, Saad Z. Usmani, Paul G. Richardson
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract The randomized, phase 2 GRIFFIN study (NCT02874742) evaluated daratumumab plus lenalidomide/bortezomib/dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM). We present final post hoc analyses (median follow-up
Externí odkaz:
https://doaj.org/article/bb6796db0ba84a22b84787f34a884f56
Autor:
Natalie S. Callander, Rebecca Silbermann, Jonathan L. Kaufman, Kelly N. Godby, Jacob Laubach, Timothy M. Schmidt, Douglas W. Sborov, Eva Medvedova, Brandi Reeves, Binod Dhakal, Cesar Rodriguez, Saurabh Chhabra, Ajai Chari, Susan Bal, Larry D. Anderson, Bhagirathbhai R. Dholaria, Nitya Nathwani, Parameswaran Hari, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Smith Giri, Luciano J. Costa, Saad Z. Usmani, Paul G. Richardson, Peter M. Voorhees
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/
Externí odkaz:
https://doaj.org/article/ebc38d6b2c3c4c4a957f6410c2bc2f56
Autor:
Ryan T. Bishop, Anna K. Miller, Matthew Froid, Niveditha Nerlakanti, Tao Li, Jeremy S. Frieling, Mostafa M. Nasr, Karl J. Nyman, Praneeth R. Sudalagunta, Rafael R. Canevarolo, Ariosto Siqueira Silva, Kenneth H. Shain, Conor C. Lynch, David Basanta
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)
Abstract Multiple myeloma (MM) is an osteolytic malignancy that is incurable due to the emergence of treatment resistant disease. Defining how, when and where myeloma cell intrinsic and extrinsic bone microenvironmental mechanisms cause relapse is ch
Externí odkaz:
https://doaj.org/article/6a891d57aa954ccea72f58bdbad908a5
Autor:
Samia Shabnaz, Trang N. Nguyen, Roy Williams, Samuel M. Rubinstein, Timothy J. Garrett, Marwa Tantawy, Michael G. Fradley, Mohammed E. Alomar, Kenneth H. Shain, Rachid C. Baz, Daniel Lenihan, Robert F. Cornell, Qing Lu, Yan Gong
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 5, Pp n/a-n/a (2024)
Abstract As a treatment for relapsed or refractory multiple myeloma (MM), carfilzomib has been associated with a significant risk of cardiovascular adverse events (CVAE). The goals of our study were to evaluate the metabolomic profile of MM patients
Externí odkaz:
https://doaj.org/article/838ef51b882e4949bbc362155f08484d
Autor:
Ryan T. Bishop, Tao Li, Raghunandan R. Alugubelli, Mostafa Nasr, Karl J. Nyman, Praneeth Sudalagunta, Mark Meads, Jeremy Frieling, Niveditha Nerlakanti, Marilena Tauro, Oliver Hampton, Bin Fang, Steven Grant, John Koomen, Ariosto Siqueira Silva, Kenneth H. Shain, Conor C. Lynch
Publikováno v:
Journal of Bone Oncology, Vol 45, Iss , Pp 100539- (2024)
Externí odkaz:
https://doaj.org/article/521fc9dd9d7d46f098490ae18ec77b15
Autor:
Marwa Tantawy, Guang Yang, Raghunandan Reddy Algubelli, Gabriel DeAvila, Samuel M. Rubinstein, Robert F. Cornell, Michael G. Fradley, Erin M. Siegel, Oliver A. Hampton, Ariosto S. Silva, Daniel Lenihan, Kenneth H. Shain, Rachid C. Baz, Yan Gong
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 10 (2023)
BackgroundProteasome inhibitor Carfilzomib (CFZ) is effective in treating patients with refractory or relapsed multiple myeloma (MM) but has been associated with cardiovascular adverse events (CVAE) such as hypertension, cardiomyopathy, and heart fai
Externí odkaz:
https://doaj.org/article/d2f22b870497486d9a0014b93469fa85
Autor:
Michelle Y. Wang, Tao Li, Yuan Ren, Bijal D. Shah, Tint Lwin, Jing Gao, Kenneth H. Shain, Wei Zhang, Xiaohong Zhao, Jianguo Tao
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 1, Pp 1-6 (2021)
Externí odkaz:
https://doaj.org/article/a4824541a9364fd0aedec5584aa9b589
Autor:
AGM Mostofa, Allison Distler, Mark B. Meads, Eva Sahakian, John J. Powers, Alexandra Achille, David Noyes, Gabriela Wright, Bin Fang, Victoria Izumi, John Koomen, Rupal Rampakrishnan, Tuan P. Nguyen, Gabriel De Avila, Ariosto S. Silva, Praneeth Sudalagunta, Rafael Renatino Canevarolo, Maria D. Coelho Siqueira Silva, Raghunandan Reddy Alugubelli, Hongyue A. Dai, Amit Kulkarni, William S. Dalton, Oliver A. Hampton, Eric A. Welsh, Jamie K. Teer, Alexandre Tungesvik, Kenneth L. Wright, Javier Pinilla-Ibarz, Eduardo M. Sotomayor, Kenneth H. Shain, Jason Brayer
Publikováno v:
JCI Insight, Vol 6, Iss 24 (2021)
The clinical utility of histone/protein deacetylase (HDAC) inhibitors in combinatorial regimens with proteasome inhibitors for patients with relapsed and refractory multiple myeloma (MM) is often limited by excessive toxicity due to HDAC inhibitor pr
Externí odkaz:
https://doaj.org/article/7fe4645c54d74f3db9e69957840e8738
Autor:
Benjamin B. Morris, Jason P. Smith, Qi Zhang, Zhijie Jiang, Oliver A. Hampton, Michelle L. Churchman, Susanne M. Arnold, Dwight H. Owen, Jhanelle E. Gray, Patrick M. Dillon, Hatem H. Soliman, Daniel G. Stover, Howard Colman, Arnab Chakravarti, Kenneth H. Shain, Ariosto S. Silva, John L. Villano, Michael A. Vogelbaum, Virginia F. Borges, Wallace L. Akerley, Ryan D. Gentzler, Richard D. Hall, Cindy B. Matsen, C. M. Ulrich, Andrew R. Post, David A. Nix, Eric A. Singer, James M. Larner, Peter Todd Stukenberg, David R. Jones, Marty W. Mayo
Publikováno v:
Biomolecules, Vol 12, Iss 11, p 1570 (2022)
In the past decade, defective DNA repair has been increasingly linked with cancer progression. Human tumors with markers of defective DNA repair and increased replication stress exhibit genomic instability and poor survival rates across tumor types.
Externí odkaz:
https://doaj.org/article/df3f2dd332a741889c5d48abf7420c89
Autor:
Jing Gao, Michelle Y. Wang, Yuan Ren, Tint Lwin, Tao Li, Joy C. Yan, Eduardo M. Sotomayor, Derek R. Duckett, Bijal D. Shah, Kenneth H. Shain, Xiaohong Zhao, Jianguo Tao
Publikováno v:
Haematologica, Vol 107, Iss 5 (2021)
Despite significant progress in the treatment of patients with diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), the prognosis of patients with relapsed disease remains poor due to the emergence of drug resistance and subsequent d
Externí odkaz:
https://doaj.org/article/9cb0750261dc4e50aaa0f54da1bd96a3